** Shares of cancer drug developer iTeos Therapeutics ITOS.O rise 4.5% to $7.15 in the afternoon trade
** Company reports Q4 net loss of $1.01 per share, compared to analysts' estimates of a loss of $1.06 per share, according to data compiled by LSEG
** ITOS expects its cash balance of $655 million to provide a runway through 2027
** ITOS down 38.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。